Flecainide-Short Long Study (Flec-SL)

NACompletedINTERVENTIONAL
Enrollment

760

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

March 31, 2011

Conditions
Atrial Fibrillation
Interventions
DRUG

Flecainide

Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.

All Listed Sponsors
collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

Meda Pharmaceuticals

INDUSTRY

collaborator

German Research Foundation

OTHER

lead

Atrial Fibrillation Network

OTHER